497 related articles for article (PubMed ID: 17854365)
1. Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.
Antinori S; Longhi E; Bestetti G; Piolini R; Acquaviva V; Foschi A; Trovati S; Parravicini C; Corbellino M; Meroni L
Br J Dermatol; 2007 Nov; 157(5):1032-6. PubMed ID: 17854365
[TBL] [Abstract][Full Text] [Related]
2. Short report: Development of post-kala-azar dermal leishmaniasis (PKDL) in miltefosine-treated visceral leishmaniasis.
Das VN; Pandey K; Verma N; Lal CS; Bimal S; Topno RK; Singh D; Siddiqui NA; Verma RB; Das P
Am J Trop Med Hyg; 2009 Mar; 80(3):336-8. PubMed ID: 19270277
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
[TBL] [Abstract][Full Text] [Related]
4. Post-kala-azar dermal leishmaniasis (PKDL), HIV and pulmonary tuberculosis.
Das VN; Pandey K; Verma N; Bimal S; Lal CS; Singh D; Das P
Natl Med J India; 2010; 23(2):88-9. PubMed ID: 20925205
[TBL] [Abstract][Full Text] [Related]
5. A clinical isolate of Leishmania donovani with ITS1 sequence polymorphism as a cause of para-kala-azar dermal leishmaniasis in an Ethiopian human immunodeficiency virus-positive patient on highly active antiretroviral therapy.
Gelanew T; Amogne W; Abebe T; Kuhls K; Hailu A; Schönian G
Br J Dermatol; 2010 Oct; 163(4):870-4. PubMed ID: 20331449
[TBL] [Abstract][Full Text] [Related]
6. Post-kala-azar dermal leishmaniasis (PKDL): the first case report from Nepal.
Karki P; Koirala S; Parija SC; Sethi M; Das ML
Southeast Asian J Trop Med Public Health; 2003 Mar; 34(1):22-3. PubMed ID: 12971510
[TBL] [Abstract][Full Text] [Related]
7. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
[TBL] [Abstract][Full Text] [Related]
8. Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection.
Gilad J; Borer A; Hallel-Halevy D; Riesenberg K; Alkan M; Schlaeffer F
Isr Med Assoc J; 2001 Jun; 3(6):451-2. PubMed ID: 11433642
[No Abstract] [Full Text] [Related]
9. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
Ramesh V; Ansari NA; Jain RK; Salotra P
Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
[No Abstract] [Full Text] [Related]
10. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine.
Kumar D; Ramesh V; Verma S; Ramam M; Salotra P
Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997
[No Abstract] [Full Text] [Related]
12. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
13. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
14. Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states.
Saurabh S; Roy P; Pandey DK; Ray D; Tarak S; Pandey R; Kumar D; Jamil S; Paulraj A; Kumar A; Dutta S
J Vector Borne Dis; 2020; 57(2):161-169. PubMed ID: 34290161
[TBL] [Abstract][Full Text] [Related]
15. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311
[TBL] [Abstract][Full Text] [Related]
16. Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART).
Tadesse A; Hurissa Z
Ethiop Med J; 2009 Jan; 47(1):77-9. PubMed ID: 19743785
[TBL] [Abstract][Full Text] [Related]
17. The safety and efficacy of miltefosine in the long-term treatment of post-kala-azar dermal leishmaniasis in South Asia - A review and meta-analysis.
Pijpers J; den Boer ML; Essink DR; Ritmeijer K
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007173. PubMed ID: 30742620
[TBL] [Abstract][Full Text] [Related]
18. Post-Kala-Azar dermal leishmaniasis in an HIV-1-infected woman: recovery after amphotericin B following failure of oral miltefosine.
Guffanti M; Gaiera G; Bossolasco S; Ceserani N; Ratti D; Cinque P; Salmaso F; Gianotti N; Lazzarin A
Am J Trop Med Hyg; 2008 Nov; 79(5):715-8. PubMed ID: 18981510
[TBL] [Abstract][Full Text] [Related]
19. Increasing incidence of post-kala-azar dermal leishmaniasis in a population-based study in Bangladesh.
Rahman KM; Islam S; Rahman MW; Kenah E; Ghalib CM; Zahid MM; Maguire J; Rahman M; Haque R; Luby SP; Bern C
Clin Infect Dis; 2010 Jan; 50(1):73-6. PubMed ID: 19951168
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis in HIV-infected patients with AIDS: a report of two cases diagnosed in the USA.
Farooq U; Choudhary S; Chacon AH; Lebrun E; Shiman MI; Hernandez J; Milikowski C; Kerdel FA; Romanelli P
Int J Dermatol; 2013 Sep; 52(9):1098-104. PubMed ID: 23834626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
